Acebutolol 100mg capsules
A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Acebutolol
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Acebutolol
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Acebutolol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
7 branded products available
WHO defined daily dose (DDD)
400 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · Randomised trials: 1 · 1975–2025
Showing the 50 most relevant studies, sorted by most relevant.
N. J. Waleng, Tshimangazo Saddam Munonde, Anele Mpupa, et al.
RSC Advances, 2025
Rapid advances in industries and agricultural practices have recently released various toxic pollutants into aquatic systems. Among other pollutants, pharmaceuticals, have been detected in environmental aquatic systems at levels that have negative health impacts on both humans and animals. This study employed an in situ chemical co-precipitation method to fabricate a magnetic amine-based metal organic framework nanocomposite. This nanocomposite was successfully synthesised and applied as a photocatalytic material for the mineralization of acebutolol (ACE) in water. The prepared materials, including the nanocomposite (Fe3O4@NH2-MIL-101(Cr)) were characterised using transmission electron microscopy (TEM), Brunauer–Emmett–Teller (BET) analysis, Fourier transform infrared spectroscopy (FTIR) and X-ray powder diffraction (XRD). The optoelectronic properties were determined using photoluminescence (PL), electrochemical impedance spectroscopy, diffuse reflectance spectroscopy (UV-Vis DRS) and ultraviolet–visible spectroscopy. The photocatalytic efficacy of the nanocomposite was assessed via the degradation of acebutolol under visible light illumination. The results indicate that adsorption–desorption equilibrium was attained after 60 min in the dark, and 98.3% degradation efficiency was achieved after 180 min with the light on. According to scavenging experiments, superoxide radicals (·O2−) were the main reactive oxygen species (ROS) during photodegradation. The Nyquist plot obtained from electrochemical impedance spectroscopy (EIS) showed that the Fe3O4@NH2-MIL-101(Cr) nanocomposite had a reduced charge transfer resistance (Rct), indicating separation and accelerated transfer of charges at the interface. The obtained electron lifespan (τe) supported the results, and was found to be higher for Fe3O4@NH2-MIL-101(Cr) compared to NH2-MIL-101(Cr) and pure Fe3O4. The photocatalytic mechanism revealed that the formed heterojunction followed a Z-scheme mechanism.
Abstract licence: CC BY-NC
Angela Yu-Chen Lin, Chih-An Lin, H. Tung, et al.
Journal of hazardous materials, 2010
Bramahn . Singh, W. R. Thoden, J. Wahl
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1982
S. Deacon, A. Karunanayake, D. Barnett
British Medical Journal, 1977
Jean‐Pierre Boissel, A. Leizorovicz, H. Picolet, et al.
The American journal of cardiology, 1990
Yanyu Zhang, Giorgia Daniel, Sonia Lanzalaco, et al.
Journal of hazardous materials, 2021
- Hydrogen Peroxide
- Water Pollutants, Chemical
- Chlorides
P. Camus, J. Lombard, M. Perrichon, et al.
Thorax, 1989
Yuvarajgouda N. Patil, Manjunatha Megalamani, S. Nandibewoor
Journal of The Electrochemical Society, 2023
W. Hsiao, Subash Vetri Selvi, Alagumalai Krishnapandi, et al.
Talanta, 2024
- Oxides
- Graphite
- Tungsten
A. M. Al-Mohaimeed, Suliman Y. Al Omar, M. El-Tohamy
Heliyon, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
10 found
Half-life
3 to 4 hours
Mechanism
Acebutolol is a selective β1-receptor antagonist.
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
40%
Half-life
3 to 4 hours
Protein binding
26%
Metabolism
Elimination
30%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1490 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Involved in the regulation of sleep/wake behaviors PMID:31473062
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
ATC C07AB04
ATC C07BB04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Acebutolol
Additional database identifiers
Drugs Product Database (DPD)
11162
Drugs Product Database (DPD)
2116
ChemSpider
1901
BindingDB
25755
HUGO Gene Nomenclature Committee (HGNC)
HGNC:285
GenAtlas
ADRB1
GeneCards
ADRB1
GenBank Gene Database
J03019
GenBank Protein Database
178200
Guide to Pharmacology
28
UniProt Accession
ADRB1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:286
GenAtlas
ADRB2
GeneCards
ADRB2
GenBank Gene Database
Y00106
GenBank Protein Database
29371
Guide to Pharmacology
29
UniProt Accession
ADRB2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2625
GenAtlas
CYP2D6
GeneCards
CYP2D6
GenBank Gene Database
M20403
GenBank Protein Database
181350
Guide to Pharmacology
1329
UniProt Accession
CP2D6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72